ARTV (Artiva Biotherapeutics) Institutional Ownership: 35.15% (As of Jul. 29, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ARTV Artiva Biotherapeutics Inc ARTV
12 GF Score
Price $10.00
! 3 Warning Signs
View Full Analysis

What is Artiva Biotherapeutics Institutional Ownership?

Artiva Biotherapeutics ARTV -4.39% 12 Institutional Ownership is 35.15% as of Jul. 29, 2026. GuruFocus rates ARTV with a GF Score™ of 12/100. The stock has 3 warning signs investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Artiva Biotherapeutics's institutional ownership is 35.15%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Artiva Biotherapeutics's Insider Ownership is 6.04%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Artiva Biotherapeutics's Float Percentage Of Total Shares Outstanding is 69.96%.

Artiva Biotherapeutics Institutional Ownership Historical Data

* Premium members only.

The historical data trend for Artiva Biotherapeutics's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Artiva Biotherapeutics Institutional Ownership Chart

Artiva Biotherapeutics Historical Data

The historical data trend for Artiva Biotherapeutics can be seen below:

2025-09-30 2025-10-31 2025-11-30 2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31 2026-06-30
Institutional Ownership 4.53 5.02 5.67 4.83 4.85 5.06 4.91 4.87 5.65 8.79
ARTV
12GF Score
Artiva Biotherapeutics Inc ARTV
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Artiva Biotherapeutics Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 35.15% mean?
Artiva Biotherapeutics (ARTV) has a Institutional Ownership of 35.15% as of Jul. 29, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Artiva Biotherapeutics and its competitors.
Is Artiva Biotherapeutics' Institutional Ownership too high?
Artiva Biotherapeutics' current Institutional Ownership is 35.15%. Overall, Artiva Biotherapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Artiva Biotherapeutics' Institutional Ownership compare to EIKN and DNA?
Artiva Biotherapeutics' Institutional Ownership of 35.15% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Biotechnology company?
A good Institutional Ownership depends on the Biotechnology industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Artiva Biotherapeutics and its competitors. Artiva Biotherapeutics's current Institutional Ownership is 35.15%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Artiva Biotherapeutics stock overvalued right now?
Artiva Biotherapeutics (ARTV) has a current Institutional Ownership of 35.15%. The current Institutional Ownership is 35.15%. Artiva Biotherapeutics' overall GF Score™ is 12/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For Artiva Biotherapeutics (ARTV), the current Institutional Ownership is 35.15% as of Jul. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Artiva Biotherapeutics Business Description

Address 5505 Morehouse Drive, Suite 100, San Diego, CA, USA, 92121
Artiva Biotherapeutics Inc is a biopharmaceutical company. The company is engaged in advancing a pipeline of off-the-shelf, allogeneic NK cell therapies for the treatment of hematologic malignancies or solid tumors. The pipeline program of the company includes Artiva-Funded Trials and Collaborator-Funded Trials. The company pipeline includes AlloNK: is an allogeneic, off-the-shelf, cryopreserved NK cell therapy candidate designed to enhance the antibody-dependent cellular cytotoxicity (ADCC) effect of mAbs to drive B-cell. Others products includes: CAR-NK(AB201),CAR-NK(AB205).
12GF Score

Get the complete analysis for ARTV

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$10.00
Price